Understanding Challenges and Needs in Refractory Chronic GVHD

Insights from 2023 ASH Annual Meeting
D

Chronic GVHD: Results from Agave-201 - Axatilimab at 3 Different Doses

By Insights from 2023 ASH Annual Meeting FEATURING Daniel Wolff
By Insights from 2023 ASH Annual Meeting FEATURING Daniel Wolff
76 views
December 29, 2023
0 Comments
Login to view comments. Click here to Login
06:18
Robert Zeiser

CSF1R's Role in Modulating Inflammation and Fibrosis in cGVHD

23:37
Rush University Medical Center

Management of Viral Infections Post-Transplant: CMV, EBV, and HHV-6

Feat. E. Bhaimia
07:22
Giuseppe Francesco Milone

Steroid-Refractory GvHD Management: When to Switch From Steroids

46:03
University of Colorado Cancer Center

CAR NK Cells: Next Generation Cell Therapies for Cancer

Feat. K. Rezvani
08:08
Jose Perez Simon

Unmet Needs in GvHD and the Role of Axatilimab

08:43
Nandita Khera

Maintaining QoL in Chronic GvHD

17:18
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Approaches to Preventing and Treating GVHD in 2024

Feat. N. Hossain
14:19
Zachariah DeFilipp

Axatilimab in Chronic GVHD: Updates From the AGAVE-201 Study

27:21
UChicago Medicine

Updates in Transplantation and GVHD From Recent Meetings

Feat. M. Nawas
31:53
Indy Hematology Review

HSCT in 2024: What Every Hematologist Needs to Know

Feat. R. Childs
14:54
Insights from 2023 ASH Annual Meeting

Clonal Hematopoiesis Is Common in Unrelated Stem Cell Donors but Has…

Feat. J. Schetelig